List of Actoplus Met Xr drug patents

Actoplus Met Xr is owned by Takeda Pharms Usa.

Actoplus Met Xr contains Metformin Hydrochloride; Pioglitazone Hydrochloride.

Actoplus Met Xr has a total of 5 drug patents out of which 0 drug patents have expired.

Actoplus Met Xr was authorised for market use on 12 May, 2009.

Actoplus Met Xr is available in tablet, extended release;oral dosage forms.

The generics of Actoplus Met Xr are possible to be released after 31 July, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8668931 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(7 months from now)

US8470368 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(7 months from now)

US9060941 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(7 months from now)

US7785627 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Jul, 2026

(3 years from now)

US7959946 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Jul, 2026

(3 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 12 May, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ACTOPLUS MET XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in